A little bit of farm, a little bit of suburbia: That's the recipe for Agritopia
'Sometimes it feels like we're animals in a zoo a little bit because people will walk by and they'll just stare, you know, like gawk at us,' Saxer said.
This is Agritopia, an 11-acre (4.5-hectare) organic farm that's all that remains after miles of alfalfa, corn, cotton, durum wheat and sugar beets were swallowed up by Phoenix's roaring development.
In this 'agrihood' — a residential community that includes a working farm — kids play outside at a school that borders vegetable fields or in communal green spaces nestled between homes. Well-dressed couples and boisterous teenagers flock for selfies and picturesque photos. Lines form at the diner featured on Guy Fieri's Food Network show. On the farm itself, people can walk the dirt roads, rent out plots to grow their own foods or buy its produce.
Some developers have turned to the agrihood concept in the past couple of decades to lure buyers with a different kind of amenity. At least 27 U.S. states and Canadian provinces had agrihoods as of a 2018 report from the Urban Land Institute, and more have cropped up since then.
Experts say agrihoods cater to buyers interested in sustainability, access to healthy food and a mix of urban and rural life. The core aim of many projects is to 'create a feeling for people,' said Matt Norris, one of the lead authors of that report.
Agritopia's founders saw change coming, and made a plan
It was the late 1990s when the family behind Agritopia saw 'the writing on the wall,' said Joe Johnston.
The family farm was some 5 miles (8 kilometers) from Gilbert then but it was clear the Phoenix area's rapid growth was going to bring development to their doorstep. With his parents mostly retired and a pair of brothers interested in doing other things, Johnston got their blessing to develop the land himself rather than simply selling it.
Johnston, with a background in design engineering, was intent on 'creating place," as he puts it. The neighborhood features narrow streets and homes within walking distance of restaurants, bars, shops, small parks and fitness businesses. The farm is at the center of it.
Melissa Checker, a professor of anthropology at City University of New York and author of a book on environmental gentrification, said agrihoods can appeal to people in different ways — their desire to feel environmentally conscious, nostalgia for an imagined idea of the past, increased interest in food 'self-sufficiency' and even a heightened desire to be safe and connected to neighbors after the COVID-19 pandemic.
'You have a kind of convergence of some commercial interests, you know, something that you can sell to people, and then also this real desire to change the way we do things,' she said.
Agritopia, but not utopia
In an ideal world, using green community space to grow food could especially benefit people who are food-insecure, Checker said. But because agrihoods are often tied to real estate prices and developers want a return on their investment, 'it's much more likely that these kinds of projects go into gentrifying neighborhoods or more affluent neighborhoods,' she said.
It's not clear just how big a role the farm plays in attracting buyers. At Agritopia, for example, few of the 500 homes participate in the farm box program that offers them first pick of seasonal fruits and vegetables. (The farm also sells at a market in downtown Gilbert and donates to a local food pantry.)
Johnston said he knew 'not everyone's going to be passionate about agriculture." That's why he was intent on creating a village where people have spaces to come together; it's up to them how much, if at all, they want to be involved in farming.
Still, farms are a selling point for developers especially across the Sun Belt who compete to offer pools, gyms, parks and other perks to would-be residents who have a wide range of planned communities to choose from, said Scott Snodgrass. He's founding partner of a developer that created Indigo, an agrihood outside Houston, and also of a company called Agmenity that runs farms for agrihood developers.
How the farm and the neighborhood intersect
As the sun rises, the farm's workers snip the roots off scallions and pull up thick bunches of lettuce and green garlic.
Before he started working at Agritopia, Ernesto Penalba didn't know all the steps involved in growing garlic — harvesting, cleaning, plus packing and transporting. 'But we only perceive it as one process. So it was really interesting to understand that,' he said, speaking in Spanish.
CC Garrett, who goes by 'Miss Hickory' when she's leading educational tours for kids on the farm, said she loves watching young people connect with their food in new ways — eating and maybe even enjoying salad for the first time or learning why you can't grow tomatoes year-round.
'It's amazing for me just because this community, it just really speaks to me, being built around an urban farm, which I think is such an important American concept,' she said.
For some who live here, this place is more than a typical neighborhood. In Agritopia's 'kid pod,' a cluster of families with 23 kids between them, parents let the young ones roam freely, knowing at least one guardian will always be looking out for them. The rest of the parents make dinner or plan a date night. Just across the street, a peach and citrus orchard sways in the breeze, occasionally wafting the smells of fruit into front yards.
Maria Padron lives in the 'kid pod' with her husband and two children. She loves living in Agritopia for the sense of camaraderie with her neighbors.
Her own family in Virginia had to give up their farm when her grandfather couldn't take care of it anymore. She wishes it had stayed in the family, but it's a vineyard now.
Asked whether she would have wanted her grandfather's land to become an agrihood, she says maybe — if it was done right.
'There's something obviously beautiful here that's going on, but there is some grief there too, if you've watched this land be a certain thing and then it changes within an instant,' Padron said.
___
Follow Melina Walling on X @MelinaWalling and Bluesky @melinawalling.bsky.social. Follow Joshua A. Bickel on Instagram, Bluesky and X @joshuabickel. Follow Annika Hammerschlag on Instagram @ahammergram.
___
The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
12 minutes ago
- The Hill
New Zealand will spend $1.6B on military aircraft in a plan to double the defense budget
WELLINGTON, New Zealand (AP) — New Zealand 's government announced new military spending Thursday of 2.7 billion New Zealand dollars ($1.6 billion) to replace aging aircraft, with senior officials who unveiled the package citing rapidly growing global tensions and a deteriorating security environment. The purchase of military planes and helicopters was the first procurement announced in a government plan, disclosed April, to double defense spending from 1% to 2% of GDP in the next decade. New Zealand's military spending has trailed that of its larger partners in the Five Eyes intelligence sharing group of countries — which includes the United States, Britain, Canada and Australia — and the bolstered budget reflects a shift in how the remote island nation is responding to strategic competition between major powers in the Pacific Ocean. The procurement includes five MH-60R Seahawk helicopters to replace the existing maritime fleet and two Airbus A321XLR aircraft, allowing the retirement of Boeing 757s that are more than 30 years old and were already secondhand when purchased. The helicopters accounted for more than NZ $2 billion of the spending, officials said. Defense Minister Judith Collins said her government would 'move at pace' to procure the helicopters directly through the United States' foreign military sales program instead of going to a wider tender. Cabinet ministers were expected to consider the final business case in 2026, she told reporters in Wellington on Thursday. It would take 'a few years' to acquire the helicopters, Collins added, because buying new meant New Zealand would need to 'wait in line.' She denied the choice to buy from the United States was an attempt to rectify the trade imbalance that has seen New Zealand goods targeted for an adjusted 15% levy when arriving in the U.S. under the Trump administration's global tariffs plan. The aging Boeing aircraft have frequently broken down while transporting New Zealand prime ministers abroad in recent years and now can only be flown short distances. The episodes are among an awkward string of incidents that have highlighted the rundown state of the country's military hardware and persistent difficulties in maintaining it due to recruitment shortfalls.


Indianapolis Star
13 minutes ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
Yahoo
14 minutes ago
- Yahoo
New Covid wave warning as cases in hospital patients soar by 31% in a fortnight
Covid cases in hospital patients have jumped by almost a third in a fortnight - sparking concerns of a new Covid wave. The number of hospital patients with respiratory symptoms testing positive for the virus has increased from 5.8 per cent on 26 July to 7.6 per cent on 10 August, according to the UK Health Security Agency (UKHSA). That marks an increase of 31 per cent in just 15 days. This percentage is known as the positivity rate and it is much higher among hospital patients with symptoms than the general public. The rise in cases in hospitals could be an indication the country is facing a new wave of infections, with epidemiologists suggesting soaring cases could be a cause for concern. 'This rise in cases reinforces the fact that the virus is still circulating and is capable of spreading,' Professor Lawrence Young, a virologist at Warwick University told The Independent. He added: 'A particular concern is the impact on infection levels as people return to work and school after the holiday season and the effect of cooler weather. This coupled with new virus variants and restricted access to free vaccines over the Autumn period is worrying.' But experts stress it is difficult to get an accurate picture as people no longer routinely test for the virus. Infectious disease expert Professor Paul Hunter, at University of East Anglia, explained that infection numbers have been drifting up and down for most of the year and he expects cases to rise as we approach the end of the year. 'We will see further increases but against a continuing declining general trend in hospitalisation and deaths. As to how many infections are occurring in the community. I have no idea as we only really test people in hospitals now,' Professor Hunter told the Independent. 'As to how many infections are occurring in the community, I have no idea as we only really test people in hospital now,' he added. Although this spike of 7.6 per cent is still lower than it was for most of the pandemic, it's much higher than it was in January when it was 2.2 per cent. In July last year, cases hit 16.6 per cent and 14.6 per cent in October last year, according to UKHSA data. The Covid vaccine is usually offered on the NHS in spring and early winter to people who need extra protection from the virus. But this year almost 13 million fewer people will be offered the booster jab. The Government is no longer offering the jab to pensioners aged 65 to 74, nor are they offering it to pregnant women or people with chronic heart disease or liver disease. This autumn the vaccine will be offered to adults over 75, residents in care homes for older adults and those who are immunosuppressed over the age of six months.